This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck Tumbles After FDA Rejects Drug

Merck's (MRK - Get Report) shares were sinking Tuesday after the Food and Drug Administration rejected the company's proposed new cholesterol treatment, a product for which the pharmaceuticals maker had high hopes.

The New Jersey-based drugmaker said regulators issued a not approvable letter for MK-0524A, an extended-release formulation of niacin and laropiprant, for the conditions primary hypercholesterolemia or mixed dyslipidemia.

Merck certainly could have used a positive ruling from the government, because in recent months the effectiveness of the cholesterol drugs Vytorin and Zetia, marketed with Schering-Plough (SGP), has been called into question, leading to worries about future revenue from the products.

"We plan to meet with the FDA and to submit additional information to enable the agency to further evaluate the benefit/risk profile of MK-0524A," said Peter Kim, executive vice president of the company and president of Merck Research Laboratories, in a prepared statement.

Shares of Merck were losing 8% to $38.11 in recent New York trading. The stock was the worst performer on the Dow Jones Industrial Average.

Despite the setback, Merck reaffirmed the 2008 financial guidance it issued last week and said it's still confident it will meet its goal of double-digit annual growth in adjusted earnings per share through 2010. Merck said on April 21 that it expects to earn $3.28 to $3.38 a share, before items, this year.

Merck also said it was encouraged that Europe's Committee for Medicinal Products for Human Use recommended marketing approval for MK-0524A in Europe. "[We] will continue to pursue approval within individual markets in the EU and around the world," Merck's Kim said.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $143.22 0.15%
BIIB $250.00 -0.31%
LLY $73.74 -0.61%
MRK $49.20 0.76%
PFE $29.12 2.00%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs